Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Inc. (Nasdaq: ZYME) announced two presentations at the upcoming EORTC-NCI-AACR Conference in Barcelona, showcasing preclinical data for their antibody-drug conjugate (ADC) candidates ZW220 and ZW251. ZW220, targeting NaPi2b, demonstrated promising activity in non-small cell lung, ovarian, and uterine cancer models. ZW251, targeting glypican-3, showed compelling results in hepatocellular carcinoma models. Both candidates utilize Zymeworks' proprietary payload, ZD06519.
Chief Scientific Officer Paul Moore expressed excitement about the progress of these next-generation ADC programs, which are on track for IND filings in 2025. This follows the recent advancement of ZW171 and ZW191, currently in Phase 1 studies. The presentations highlight Zymeworks' ongoing development of novel biotherapeutics for difficult-to-treat cancers and other diseases.
Zymeworks Inc. (Nasdaq: ZYME) ha annunciato due presentazioni alla prossima Conferenza EORTC-NCI-AACR a Barcellona, che metteranno in mostra dati preclinici per i loro candidati a coniugati anticorpo-farmaco (ADC) ZW220 e ZW251. ZW220, che mira a NaPi2b, ha dimostrato un'attività promettente in modelli di carcinoma polmonare non a piccole cellule, cancro ovarico e cancro uterino. ZW251, che prende di mira il glipican-3, ha mostrato risultati rilevanti in modelli di carcinoma epatocellulare. Entrambi i candidati utilizzano il caricatore proprietario di Zymeworks, ZD06519.
Il Chief Scientific Officer Paul Moore ha espresso entusiasmo per i progressi di questi programmi ADC di nuova generazione, che sono in fase di preparazione per richieste di IND nel 2025. Questo segue il recente avanzamento di ZW171 e ZW191, attualmente in studi di Fase 1. Le presentazioni evidenziano lo sviluppo continuo da parte di Zymeworks di bioterapeutici innovativi per tumori difficili da trattare e altre malattie.
Zymeworks Inc. (Nasdaq: ZYME) anunció dos presentaciones en la próxima Conferencia EORTC-NCI-AACR en Barcelona, que mostrarán datos preclínicos para sus candidatos de conjugados anticuerpo-fármaco (ADC) ZW220 y ZW251. ZW220, que se dirige a NaPi2b, demostró una actividad prometedora en modelos de cáncer de pulmón de células no pequeñas, cáncer de ovario y cáncer uterino. ZW251, que apunta a glypican-3, mostró resultados contundentes en modelos de carcinoma hepatocelular. Ambos candidatos utilizan la carga propietaria de Zymeworks, ZD06519.
El Director Científico Paul Moore expresó su entusiasmo por el progreso de estos programas de ADC de próxima generación, que están en camino para presentaciones de IND en 2025. Esto sigue al reciente avance de ZW171 y ZW191, que actualmente están en estudios de Fase 1. Las presentaciones destacan el desarrollo continuo de Zymeworks de bioterapéuticos novedosos para cánceres difíciles de tratar y otras enfermedades.
자이뮤웍스 Inc. (Nasdaq: ZYME)는 바르셀로나에서 열리는 EORTC-NCI-AACR 컨퍼런스에서 항체-약물 접합체(ADC) 후보 ZW220 및 ZW251에 대한 전임상 데이터를 선보일 예정이라고 발표했습니다. NaPi2b를 목표로 하는 ZW220은 비소세포 폐암, 난소암 및 자궁암 모델에서 유망한 활성을 보여주었습니다. glypican-3를 목표로 하는 ZW251은 간세포 암 모델에서 설득력 있는 결과를 보였습니다. 두 후보는 자이뮤웍스의 독자적인 페이로드인 ZD06519를 활용하고 있습니다.
수석 과학 책임자 폴 무어는 2025년 IND 제출 계획에 대한 기대감을 표현했습니다. 이는 현재 1상 연구에 있는 ZW171과 ZW191의 최근 발전을 따릅니다. 이 발표는 치료하기 어려운 암과 기타 질병을 위한 새로운 생물 치료제 개발에 있어 자이뮤웍스의 지속적인 노력을 강조합니다.
Zymeworks Inc. (Nasdaq: ZYME) a annoncé deux présentations lors de la prochaine conférence EORTC-NCI-AACR à Barcelone, présentant des données précliniques pour leurs candidats de conjugués anticorps-médicaments (ADC) ZW220 et ZW251. ZW220, ciblant NaPi2b, a montré une activité prometteuse dans des modèles de cancer du poumon non à petites cellules, de cancer des ovaires et de cancer de l'utérus. ZW251, ciblant le glypican-3, a montré des résultats convaincants dans des modèles de carcinome hépatocellulaire. Les deux candidats utilisent la charge propriétaire de Zymeworks, ZD06519.
Paul Moore, directeur scientifique, a exprimé son enthousiasme pour les progrès de ces programmes ADC de nouvelle génération, qui sont en bonne voie pour des demandes d'IND en 2025. Cela suit les récentes avancées de ZW171 et ZW191, qui sont actuellement en études de phase 1. Les présentations mettent en évidence le développement continu par Zymeworks de biothérapeutiques novateurs pour des cancers difficiles à traiter et d'autres maladies.
Zymeworks Inc. (Nasdaq: ZYME) gab zwei Präsentationen auf der bevorstehenden EORTC-NCI-AACR-Konferenz in Barcelona bekannt, bei denen präklinische Daten zu ihren Antikörper-Wirkstoff-Konjugaten (ADC) ZW220 und ZW251 vorgestellt werden. ZW220, das auf NaPi2b abzielt, zeigte vielversprechende Aktivitäten in Modellen für Lungenkrebs in nicht kleinzelliger Form, Eierstockkrebs und Gebärmutterkrebs. ZW251, das auf Glypikan-3 abzielt, zeigte überzeugende Ergebnisse in Modellen des hepatozellulären Karzinoms. Beide Kandidaten nutzen den proprietären Wirkstoff von Zymeworks, ZD06519.
Der Chief Scientific Officer Paul Moore äußerte sich begeistert über die Fortschritte dieser ADC-Programme der nächsten Generation, die auf dem Weg zu IND-Anträgen im Jahr 2025 sind. Dies folgt auf den jüngsten Fortschritt von ZW171 und ZW191, die sich derzeit in Phase-1-Studien befinden. Die Präsentationen unterstreichen die kontinuierliche Entwicklung neuartiger biotherapeutischer Ansätze von Zymeworks für schwer zu behandelnde Krebserkrankungen und andere Krankheiten.
- Preclinical data for ZW220 shows promising activity in multiple cancer models
- ZW251 demonstrates compelling results in hepatocellular carcinoma models
- Both ADC candidates are on track for IND filings in 2025
- ZW171 and ZW191 have advanced to Phase 1 clinical studies
- None.
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms
VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat cancers and other diseases, today announced two presentations highlighting results from recent preclinical research for Zymeworks’ antibody-drug conjugate candidates ZW220 and ZW251. Results will be presented at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference in Barcelona being held October 23-25, 2024.
"We are excited to share results from our preclinical studies, which highlight the activity of ZW220 in models of non-small cell lung, ovarian, and uterine cancers, as well as ZW251 in hepatocellular carcinoma models, both of which leverage our novel proprietary payload, ZD06519," said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. "We are encouraged by the progress of these next-generation ADC programs, which remain on track for IND filings in 2025, following the recent advancement of ZW171 and ZW191, which are currently recruiting for Phase 1 studies.”
Oral Presentation Details:
Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
Session Title: Proffered Papers: New Drugs on the Horizon
Date: Friday, October 25
Time: 12:00-12:12 pm Central European Summer Time (CEST)
Poster Presentation Details:
Title: ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
Session Title: Antibody-Drug Conjugates
Presentation number: PB165
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to anticipated preclinical data presentations; the timing and status of ongoing and future studies and the release of data; expectations regarding future regulatory filings and approvals and the timing thereof; the timing of and results of interactions with regulators; anticipated regulatory submissions and the timing thereof; Zymeworks’ preclinical pipeline; the anticipated benefits of the collaboration agreements with Jazz and BeiGene; the commercial potential of technology platforms and product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the potential addressable market of zanidatamab; potential safety profile and therapeutic effects of zanidatamab and Zymeworks’ other product candidates; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com).
Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
What are the main antibody-drug conjugate candidates Zymeworks (ZYME) is presenting at the EORTC-NCI-AACR Conference?
What types of cancer models has ZW220 shown activity in for Zymeworks (ZYME)?
What is the target for Zymeworks' (ZYME) ZW251 antibody-drug conjugate?
When does Zymeworks (ZYME) expect to file INDs for ZW220 and ZW251?
Which Zymeworks (ZYME) antibody-drug conjugates are currently in Phase 1 clinical studies?
